Global Human Hepatitis B Immunoglobulin Market Insights and Forecast to 2028
SKU ID : QYR-20051897 | Publishing Date : 31-Jan-2022 | No. of pages : 109
Due to the COVID-19 pandemic, the global Human Hepatitis B Immunoglobulin market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) accounting for % of the Human Hepatitis B Immunoglobulin global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hepatitis B Carrier segment is altered to an % CAGR throughout this forecast period.
China Human Hepatitis B Immunoglobulin market size is valued at US$ million in 2021, while the US and Europe Human Hepatitis B Immunoglobulin are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Human Hepatitis B Immunoglobulin landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Human Hepatitis B Immunoglobulin include Baxter, CSL, Bayer, Grifols, Octapharma, Shanghai RAAS, Hualan Biological, China Biologic and Tiantan Biologic, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Human Hepatitis B Immunoglobulin Scope and Segment
Human Hepatitis B Immunoglobulin market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Human Hepatitis B Immunoglobulin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
Segment by Application
Hepatitis B Carrier
Hepatitis B Close Contacts
By Company
Baxter
CSL
Bayer
Grifols
Octapharma
Shanghai RAAS
Hualan Biological
China Biologic
Tiantan Biologic
Shuanglin Bio-pharmacy
Sichuan Yuanda Shuyang
Boya Bio-pharmaceutical
Shanghai Institute of Biological
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Frequently Asked Questions
- By product type
- By End User/Applications
- By Technology
- By Region